glp 1 eye disease GLP-1 Meds Reduce Risk of Uveitis Updated guidance from the PCDS
Description
Batterham RL, Cummings DE
doi: 10.12932/ap-290821-1217 [DOI] [PubMed] [Google Scholar] 41
This is the first time GLP-1s (glucagon-like peptide-1 receptor agonists) will be covered by insurance when used solely for weight loss
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: Population based cohort study
Semaglutide was also associated with a 4.5- to 6.4-kg weight loss
